Pulse Biosciences (PLSE) Downgraded to “Sell” at BidaskClub

BidaskClub lowered shares of Pulse Biosciences (NASDAQ:PLSE) from a hold rating to a sell rating in a research note published on Thursday.

Separately, ValuEngine upgraded Pulse Biosciences from a sell rating to a hold rating in a research report on Sunday, December 31st.

Pulse Biosciences (NASDAQ PLSE) traded up $1.00 during trading on Thursday, reaching $23.84. The company had a trading volume of 71,400 shares, compared to its average volume of 91,450. The stock has a market capitalization of $387.02 and a PE ratio of -17.03. Pulse Biosciences has a 12 month low of $5.82 and a 12 month high of $39.50.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.52) EPS for the quarter.

In related news, Director Maky Zanganeh purchased 4,000 shares of Pulse Biosciences stock in a transaction on Tuesday, December 12th. The stock was acquired at an average price of $23.07 per share, for a total transaction of $92,280.00. Following the completion of the transaction, the director now directly owns 332,500 shares in the company, valued at approximately $7,670,775. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Robert W. Duggan purchased 22,901 shares of Pulse Biosciences stock in a transaction on Thursday, October 19th. The stock was bought at an average price of $22.79 per share, with a total value of $521,913.79. Following the transaction, the insider now owns 5,820,513 shares of the company’s stock, valued at $132,649,491.27. The disclosure for this purchase can be found here. Corporate insiders own 6.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Schwab Charles Investment Management Inc. purchased a new stake in Pulse Biosciences in the second quarter worth about $529,000. Rhumbline Advisers purchased a new stake in Pulse Biosciences in the second quarter worth about $325,000. Bank of New York Mellon Corp bought a new position in shares of Pulse Biosciences in the second quarter worth about $897,000. Wells Fargo & Company MN boosted its stake in shares of Pulse Biosciences by 21,473.2% in the second quarter. Wells Fargo & Company MN now owns 53,933 shares of the company’s stock worth $1,862,000 after acquiring an additional 53,683 shares during the period. Finally, Teachers Advisors LLC bought a new position in shares of Pulse Biosciences in the second quarter worth about $566,000. Institutional investors and hedge funds own 9.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pulse Biosciences (PLSE) Downgraded to “Sell” at BidaskClub” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2018/01/08/pulse-biosciences-plse-downgraded-to-sell-at-bidaskclub.html.

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit